Hyperpolarised MR technologies and molecular probes as alternatives for conventional metal-containing contrast agents for MRI examinations
The European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) recommended suspension and warning labels for Gadolinium (Gd)-bearing CAs (GBCA) used in magnetic resonance imaging (MRI).To address this iminent health concern, we seek to develop hyperpolarised MR technologies and molecular probes as alternatives for conventional metal-containing contrast agents for MRI examinations, as part of a multidisciplinary collaboration led by an international consortium